PT2419104T - Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos - Google Patents

Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos

Info

Publication number
PT2419104T
PT2419104T PT107137903T PT10713790T PT2419104T PT 2419104 T PT2419104 T PT 2419104T PT 107137903 T PT107137903 T PT 107137903T PT 10713790 T PT10713790 T PT 10713790T PT 2419104 T PT2419104 T PT 2419104T
Authority
PT
Portugal
Prior art keywords
combinations
treatment
receptor agonists
cognitive disorders
acetylcholinesterase inhibitors
Prior art date
Application number
PT107137903T
Other languages
English (en)
Portuguese (pt)
Inventor
Beattie David
Shen Fei
A M Smith Jacqueline
Murray Mckinnell Robert
Chang Ray
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of PT2419104T publication Critical patent/PT2419104T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT107137903T 2009-04-13 2010-04-12 Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos PT2419104T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06

Publications (1)

Publication Number Publication Date
PT2419104T true PT2419104T (pt) 2018-01-31

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107137903T PT2419104T (pt) 2009-04-13 2010-04-12 Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos

Country Status (24)

Country Link
US (2) US8404711B2 (enExample)
EP (1) EP2419104B1 (enExample)
JP (1) JP2012523437A (enExample)
KR (1) KR20120017421A (enExample)
CN (2) CN105832735A (enExample)
AU (1) AU2010236734B2 (enExample)
BR (1) BRPI1013777A8 (enExample)
CA (1) CA2758321A1 (enExample)
CY (1) CY1119800T1 (enExample)
DK (1) DK2419104T3 (enExample)
ES (1) ES2654930T3 (enExample)
HR (1) HRP20180018T1 (enExample)
HU (1) HUE038141T2 (enExample)
IL (1) IL215660A0 (enExample)
LT (1) LT2419104T (enExample)
MX (1) MX2011010782A (enExample)
NO (1) NO2419104T3 (enExample)
PL (1) PL2419104T3 (enExample)
PT (1) PT2419104T (enExample)
RU (1) RU2569056C2 (enExample)
SI (1) SI2419104T1 (enExample)
SM (1) SMT201800036T1 (enExample)
WO (1) WO2010120695A2 (enExample)
ZA (1) ZA201107490B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA2744278C (en) 2008-11-19 2015-09-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US20150306158A1 (en) 2012-08-16 2015-10-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
MX385719B (es) 2017-05-24 2025-03-18 H Lundbeck As Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4
SG11201909359YA (en) 2017-06-01 2019-11-28 Eisai R&D Man Co Ltd Pharmaceutical composition comprising pde9 inhibitor
EP3632431A4 (en) 2017-06-02 2020-06-03 FUJIFILM Toyama Chemical Co., Ltd. Agent for preventing or treating brain atrophy
SI3661518T1 (sl) * 2017-07-31 2025-01-31 Alfasigma S.P.A. Načini zdravljenja simptomov gastropareze z zdravilom velusetrag

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1311272T3 (da) * 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
LT2419104T (lt) 2018-02-12
ES2654930T3 (es) 2018-02-15
JP2012523437A (ja) 2012-10-04
NO2419104T3 (enExample) 2018-04-07
EP2419104B1 (en) 2017-11-08
RU2011146032A (ru) 2013-05-20
HUE038141T2 (hu) 2018-10-29
PL2419104T3 (pl) 2018-04-30
EP2419104A2 (en) 2012-02-22
WO2010120695A2 (en) 2010-10-21
DK2419104T3 (en) 2018-02-05
BRPI1013777A2 (pt) 2016-04-05
CA2758321A1 (en) 2010-10-21
HRP20180018T1 (hr) 2018-02-09
IL215660A0 (en) 2012-01-31
US20100261752A1 (en) 2010-10-14
CN102395371A (zh) 2012-03-28
SI2419104T1 (en) 2018-03-30
MX2011010782A (es) 2012-01-20
SMT201800036T1 (it) 2018-03-08
AU2010236734A8 (en) 2012-02-16
US8404711B2 (en) 2013-03-26
WO2010120695A3 (en) 2010-12-02
ZA201107490B (en) 2012-06-27
AU2010236734A1 (en) 2011-11-03
CN105832735A (zh) 2016-08-10
KR20120017421A (ko) 2012-02-28
US20140057939A1 (en) 2014-02-27
AU2010236734B2 (en) 2015-06-11
CY1119800T1 (el) 2018-06-27
RU2569056C2 (ru) 2015-11-20
BRPI1013777A8 (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
SMT201800036T1 (it) Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitivi
PT2467372T (pt) Tratamento de distúrbios relacionados com bdnf usando laquinimod
EP2293800A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES
IL216140A0 (en) Egfr inhibitors and methods of treating disorders
ZA201202500B (en) Use of toll-like receptor and agonist for treating cancer
ZA201001193B (en) 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders
EP2456868A4 (en) METHOD AND COMPOSITIONS FOR TREATING SUFFERING OF SUFFERING THROUGH MUSCARIN RECEPTOR ACTIVATION
IL217777A0 (en) Methods for treatment of pain
SMT201700451T1 (it) Antagonisti di wnt e metodi di trattamento
IL216281A0 (en) Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
IL214455A0 (en) Methods and compositions for treatment of neovascularization
ZA201201290B (en) Methods and compositions for treatment of pulmonary fibrotic disorders
LT2427193T (lt) Pde7 inhibitoriaus panaudojimas judėjimo sutrikimų gydymui
IL214745A0 (en) Treatment of insulin-resistant disorders
IL219483A0 (en) Methods and compositions for rapid treatment of otitis externa
EP2475390A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
IL217297A0 (en) 5-ht3 receptor modulators, methods of making, and use thereof
IL214291A0 (en) Use of deferiprone for treatment and prevention of iron-related eye disorders
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
BR112013001939A2 (pt) tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase
IL209658A0 (en) Compositions and methods for treatment of ear disorders
HK1167106A (en) Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
HK1177888A (en) 5-ht4 receptor agonists for the treatment of dementia
GB0905954D0 (en) Treatment of exacerbations of asthma
GB0906222D0 (en) Methods for screening of therapeutic agents